Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran

2018 ◽  
Vol 120 (6) ◽  
pp. 9588-9593 ◽  
Author(s):  
Mohammad Fereidouni ◽  
Maryam Moossavi ◽  
Touba Kazemi ◽  
Shaghayeghsadat Nouranihassankiade ◽  
Arghavan Asghari
Keyword(s):  
Maintenance Dose ◽  
Warfarin Maintenance Dose

scholarly journals Influence of NQO1 Polymorphisms on Warfarin Maintenance Dose: A Systematic Review and Meta-Analysis (rs1800566 and rs10517)

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Lihong Tian ◽  
Pingping Xiao ◽  
Bingrong Zhou ◽  
Yishan Chen ◽  
Lijuan Kang ◽  
...  
Keyword(s):  
Maintenance Dose ◽  
Meta Analysis ◽  
Warfarin Dose ◽  
Maintenance Dosage ◽  
Sensitivity Analyses ◽  
Cochrane Library ◽  
The Cochrane Library ◽  
The Relationship ◽  
Review Manager ◽  
Warfarin Maintenance Dose

This meta-analysis was conducted to analyze the effect of NQO1 polymorphism on the warfarin maintenance dosage. Using strict inclusion and exclusion criteria, we searched PubMed, EMBASE, and the Cochrane Library for eligible studies published prior to July 7, 2021. The required data were extracted, and experts were consulted when necessary. Review Manager Version 5.4 software was used to analyze the relationship between NQO1 polymorphisms and the warfarin maintenance dosage. Four articles involving 757 patients were included in the meta-analysis. Patients who were NQO1 rs10517 G carriers (AG carriers or GG carriers) required a 48% higher warfarin maintenance dose than those who were AA carriers. Patients with NQO1 rs1800566 CT carriers required a 13% higher warfarin dose than those who were CC carriers, with no associations observed with the other comparisons of the NQO1 rs1800566 genotypes. However, the results obtained by comparing the NQO1 rs1800566 genotypes require confirmation, as significant changes in the results were found in sensitivity analyses. Our meta-analysis suggests that the NQO1 rs10517and NQO1 rs1800566 variant statuses affect the required warfarin maintenance dose.

The effect of the plasma levels of proteins C and S on the prediction of warfarin maintenance dose requirements

1992 ◽  
Vol 52 (1) ◽  
pp. 42-49 ◽  
Author(s):  
Aharon Lubetsky ◽  
Uri Seligsohn ◽  
David Ezra ◽  
Hillel Halkin
Keyword(s):  
Plasma Levels ◽  
Maintenance Dose ◽  
Warfarin Maintenance Dose

Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients

2009 ◽  
Vol 19 (3) ◽  
pp. 226-234 ◽  
Author(s):  
Sheng-Wen Huang ◽  
Hai-Sheng Chen ◽  
Xian-Qun Wang ◽  
Ling Huang ◽  
Ding-Li Xu ◽  
...  
Keyword(s):  
Prospective Study ◽  
Maintenance Dose ◽  
Chinese Patients ◽  
A Prospective Study ◽  
Warfarin Maintenance Dose

scholarly journals Estimation of Warfarin Maintenance Dose Based on VKORC1 (−1639 G>A) and CYP2C9 Genotypes

2007 ◽  
Vol 53 (7) ◽  
pp. 1199-1205 ◽  
Author(s):  
Yusheng Zhu ◽  
Michael Shennan ◽  
Kristen K Reynolds ◽  
Nancy A Johnson ◽  
Matthew R Herrnberger ◽  
...  
Keyword(s):  
Body Weight ◽  
Maintenance Dose ◽  
Plasma Concentrations ◽  
Warfarin Dose ◽  
Positive Association ◽  
Additional Contribution ◽  
Allele Specific ◽  
Study Population ◽  
Warfarin Maintenance Dose ◽  
Low Dosage

Abstract Background: CYP2C9 polymorphisms are associated with decreased S-warfarin clearance and lower maintenance dosage. Decreased expression of VKORC1 resulting from the −1639G>A substitution has also been implicated in lower warfarin dose requirements. We investigated the additional contribution of this polymorphism to the variance in warfarin dose. Methods: Sixty-five patients with stable anticoagulation were genotyped for CYP2C9 and VKORC1 with Tag-It™ allele-specific primer extension technology. Plasma S-warfarin concentrations and warfarin maintenance dose were compared among patients on the basis of the VKORC1 −1639G>A genotype. Results: Eighty percent of CYP2C9*1/*1 patients stabilized on <4.0 mg/day warfarin had at least 1 VKORC1 −1639A allele. Mean warfarin doses (SD) were 6.7 (3.3), 4.3 (2.2), and 2.7 (1.2) mg/day for patients with the VKORC1 −1639GG, GA, and AA genotypes, respectively. Steady-state plasma concentrations of S-warfarin were lowest in patients with the VKORC1 −1639AA genotype and demonstrated a positive association with the VKORC1 −1639G allele copy number (trend P = 0.012). A model including VKORC1 and CYP2C9 genotypes, age, sex, and body weight accounted for 61% of the variance in warfarin daily maintenance dose. Conclusions: The VKORC1 −1639A allele accounts for low dosage requirements of most patients without a CYP2C9 variant. Higher plasma S-warfarin concentrations corresponding to increased warfarin maintenance dosages support a hypothesis for increased expression of the VKORC1 −1639G allele. VKORC1 and CYP2C9 genotypes, age, sex, and body weight account for the majority of variance in warfarin dose among our study population.

Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients

2019 ◽  
Vol 75 (7) ◽  
pp. 901-911 ◽  
Author(s):  
Maki Sasano ◽  
Masako Ohno ◽  
Yuya Fukuda ◽  
Shinpei Nonen ◽  
Sachiko Hirobe ◽  
...  
Keyword(s):  
Maintenance Dose ◽  
Japanese Patients ◽  
Warfarin Maintenance Dose

Simultaneous Use of Amiodarone Influences Warfarin Maintenance Dose but Is Not Associated with Adverse Events

2014 ◽  
Vol 20 (4) ◽  
pp. 376-381 ◽  
Author(s):  
Paulo Caleb Junior Lima Santos ◽  
Renata Alonso Gadi Soares ◽  
Celia Maria Cassaro Strunz ◽  
Max Grinberg ◽  
João Fernando M. Ferreira ◽  
...  
Keyword(s):  
Adverse Events ◽  
Maintenance Dose ◽  
Simultaneous Use ◽  
Warfarin Maintenance Dose
Sign in / Sign up

Export Citation Format

Share Document